TITLE

Over budget, overdue and, perhaps, overdesigned

AUTHOR(S)
Magnus, Ben
PUB. DATE
March 2008
SOURCE
CMAJ: Canadian Medical Association Journal;3/25/2008, Vol. 178 Issue 7, p813
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the difficulties being faced by the Canada's Multipurpose Applied Physics Lattice Experiment (MAPPLE) reactors dedicated to the production of medical isotopes. The MAPPLE is capable of supplying Canada with medical isotopes used for diagnostics and the destruction of tumours through gamma rays or drugs, yet its operation is still unclear due to some problems in terms of finances. The MAPPLE has been vested with the Atomic Energy of Canada Ltd. (AECL) but the government moved to private it in the late 1980s and bought in 1991 in the form of MDS Health Group Inc. for $165 million. Moreover, renegotiation between MDS Nordion and AECL took place in 2005 and agreed on the transfer of ownership of the Dedicated Isotope Facility to AECL in exchange for $68 million.
ACCESSION #
31315689

 

Related Articles

  • AECL restarts Chalk River reactor. McCarty, Mark // Medical Device Daily;8/20/2010, Vol. 14 Issue 162, p8 

    The article reports on the decision of Atomic Energy of Canada Limited to restart its operations at the Chalk River reactor, which aims to help restore something resembling enough stream of a vital medical isotope to medical centers and clinics around the world.

  • Medical isotope shortage may be major diagnostic setback. FORD, OMAR // Medical Device Daily;6/16/2009, Vol. 13 Issue 114, p1 

    The article reports on the impact of the continued shortage of medical isotopes diagnostic imaging. Speakers at a press conference held by the Society of Nuclear Medicine noted that the shortage could revive invasive and expensive imaging techniques in diagnosing patients. The press conference...

  • Chalk River plant to cease production of molybdenum-99. McCARTY, MARK // Medical Device Daily;5/27/2009, Vol. 13 Issue 100, p2 

    The article unveils the plan of Atomic Energy of Canada (AEC) to close its Chalk River reactor in Ontario after the discovery of persistent leaks in the reactor. The company said that the remaining inventory of molybdenum-99 was removed from the reactor and will be processed immediately into...

  • Canadian hospitals rise to the occasion during isotope shortage. Collier, Roger // CMAJ: Canadian Medical Association Journal;3/25/2008, Vol. 178 Issue 7, p815 

    The article reports on the rise of Canadian Hospitals during the shortage of medical isotope supply as determined by Andrew Ross of the Halifax and Nova Scotia―based Queen Elizabeth II Health Sciences Centre. It mentions that there had been no advance warning or news from Atomic Energy of...

  • Taking the public pulse. Bird, Wendy // Northern Ontario Business;Feb96, Vol. 16 Issue 4, p12 

    Looks at a concept developed to dispose of nuclear waste in the Canadian Shield by the Atomic Energy of Canada Limited (AECL). Comments from AECL public affairs officer Larry Shewchuk; Review panel holding public hearings in southern Ontario; What the hearings will give concerned residents;...

  • Residents nix nuclear waste. Bird, Wendy // Northern Ontario Business;Feb98, Vol. 18 Issue 3, p11 

    States that Atomic Energy of Canada Limited (AECL), a government body is developing a concept detailing how to permanently dispose of nuclear waste in the Canadian Shield dispite the no-vote given to the site by Thunder Bay voters. Details on the review being given to the plans by the Canadian...

  • Engineering Antibodies for Therapy. Presta, Leonard G. // Current Pharmaceutical Biotechnology;Sep2002, Vol. 3 Issue 3, p237 

    With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher...

  • Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Huang, R; Zhao, Z; Ma, X; Li, S; Gong, R; Kuang, A // Cancer Gene Therapy;Feb2011, Vol. 18 Issue 2, p144 

    To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene under control of the survivin promoter...

  • Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. Arslan, Nuri; Emi, Mustafa; Alagöz, Engin; Üstünsöz, Bahri; Oysul, Kaan; Arpaci, Fikret; Uğurel, Şahin; Beyzadeoğlu, Murat; Özgüven, Mehmet Ali // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Apr2011, Vol. 68 Issue 4, p341 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics